초록 ▼

The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may b

The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.

대표청구항 ▼

1. An active substance in particulate form suitable for administration via a dry powder inhaler, the particulates comprising: a volume mean aerodynamic diameter of less than 7 microns;a bulk powder density within a range from about 0.1 g/cm3 to about 0.5 g/cm3; anda surface-to-volume ratio of at lea

1. An active substance in particulate form suitable for administration via a dry powder inhaler, the particulates comprising: a volume mean aerodynamic diameter of less than 7 microns;a bulk powder density within a range from about 0.1 g/cm3 to about 0.5 g/cm3; anda surface-to-volume ratio of at least 2.5 times that of spherical particles of a corresponding volume diameter, wherein the particulates are solid, non-hollow, non-porous particles and the active substance is selected from the group consisting of insulin, pro-insulin, mono-acylated insulin, insulinotropin, and insulin-like growth factor. 2. The active substance of claim 1, further comprising a shape factor of at least 2. 3. The active substance of claim 1, further comprising a shape coefficient of greater than 10. 4. The active substance of claim 1, further comprising an aerodynamic shape factor of at least 1.4. 5. The active substance of claim 1, further comprising a specific surface area of at least 10 m2/g. 6. The active substance of claim 5, wherein the specific surface area is at least 15 m2/g. 7. The active substance of claim 6, wherein the specific surface area is at least 20 m2/g. 8. The active substance of claim 7, wherein the specific surface area is at least 25 m2/g. 9. The active substance of claim 1, further comprising a volume mean diameter of less than 6 microns. 10. The active substance of claim 1, further comprising a specific surface energy of less than 100 mJ/m2. 11. The active substance of claim 10, wherein the specific surface energy is less than 70 mJ/m2. 12. The active substance of claim 1, wherein the active substance is insulin. 13. The active substance of claim 1, wherein the active substance is pro-insulin. 14. The active substance of claim 1, wherein the active substance is mono-acylated insulin. 15. The active substance of claim 1, wherein the active substance is insulinotropin. 16. The active substance of claim 1, wherein the active substance is insulin-like growth factor. 17. The active substance of claim 1, further comprising a RMS roughness, measured using AFM, of 0.5 nm or less. 18. The active substance of claim 1, further comprising a particle size distribution (X90) within a range from about 0.5 μm to about 10 μm. 19. The active substance of claim 1, further comprising an amorphous phase content of less than 1% w/w. 20. The active substance of claim 1, wherein the bulk powder density is about 0.2 g/cm3 or less. 21. The active substance of claim 1, further comprising a shape factor of at least 3.5. 22. The active substance of claim 1, further comprising a RMS roughness, measured using atomic force microscopy, of about 0.2 nm or less. 23. The active substance of claim 1, which when delivered using a passive dry powder inhaler yields a fine particle fraction in an emitted dose of about 20% or greater. 24. The active substance of claim 23, wherein the fine particle fraction is about 31% or greater. 25. The active substance of claim 24, wherein the fine particle fraction is about 55% or greater. 26. An active substance in particulate form suitable for administration via a dry powder inhaler, the particulates comprising: a volume mean aerodynamic diameter of less than 7 microns;a bulk powder density within a range from about 0.1 g/cm3 to about 0.5 g/cm3; anda surface-to-volume ratio of at least 2.5 times that of spherical particles of a corresponding volume diameter, wherein the particulates are solid, non-hollow, non-porous particles and the active substance is selected from the group consisting of amphotericin-B, parathyroid hormone, glucagon-like peptide, and an anti-infective agent. 27. The active substance of claim 26, wherein the active substance is the amphotericin-B. 28. The active substance of claim 26, wherein the active substance is the parathyroid hormone. 29. The active substance of claim 26, wherein the active substance is the glucagon-like peptide. 30. The active substance of claim 26, wherein the active substance is the anti-infective agent. 31. The active substance of claim 30, wherein the anti-infective agent comprises an aminoglycoside. 32. The active substance of claim 30, wherein the anti-infective agent comprises tobramycin. 33. The active substance of claim 30, wherein the anti-infective agent comprises a fluoroquinolone. 34. The active substance of claim 30, wherein the anti-infective agent comprises ciprofloxacin. 35. The active substance of claim 26, further comprising a specific surface area of at least 10 m2/g. 36. The active substance of claim 35, wherein the specific surface area is at least 20 m2/g. 37. The active substance of claim 36, wherein the specific surface area is at least 25 m2/g. 38. An active substance in particulate form suitable for administration via a dry powder inhaler, the particulates comprising: a volume mean aerodynamic diameter of less than 7 microns;a bulk powder density within a range from about 0.1 g/cm3 to about 0.5 g/cm3; anda surface-to-volume ratio of at least 2.5 times that of spherical particles of a corresponding volume diameter, wherein the particulates are solid, non-hollow, non-porous particles and the active substance is selected from the group consisting of salbutamol, terbutalene, salmeterol, fenoterol, and bromocriptine. 39. The active substance of claim 38, wherein the active substance is salbutamol. 40. The active substance of claim 38, wherein the active substance is bromocriptine. 41. The active substance of claim 38, wherein the active substance is terbutalene, salmeterol, or fenoterol. 42. The active substance of claim 38, further comprising a specific surface area of at least 10 m2/g. 43. The active substance of claim 42, wherein the specific surface area is at least 20 m2/g. 44. The active substance of claim 43, wherein the specific surface area is at least 25 m2/g.